These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21531236)

  • 1. Adverse events during the Scleroderma Lung Study.
    Furst DE; Tseng CH; Clements PJ; Strange C; Tashkin DP; Roth MD; Khanna D; Li N; Elashoff R; Schraufnagel DE;
    Am J Med; 2011 May; 124(5):459-67. PubMed ID: 21531236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclophosphamide versus placebo in scleroderma lung disease.
    Tashkin DP; Elashoff R; Clements PJ; Goldin J; Roth MD; Furst DE; Arriola E; Silver R; Strange C; Bolster M; Seibold JR; Riley DJ; Hsu VM; Varga J; Schraufnagel DE; Theodore A; Simms R; Wise R; Wigley F; White B; Steen V; Read C; Mayes M; Parsley E; Mubarak K; Connolly MK; Golden J; Olman M; Fessler B; Rothfield N; Metersky M;
    N Engl J Med; 2006 Jun; 354(25):2655-66. PubMed ID: 16790698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
    Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
    Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
    Khanna D; Clements PJ; Furst DE; Chon Y; Elashoff R; Roth MD; Sterz MG; Chung J; FitzGerald JD; Seibold JR; Varga J; Theodore A; Wigley FM; Silver RM; Steen VD; Mayes MD; Connolly MK; Fessler BJ; Rothfield NF; Mubarak K; Molitor J; Tashkin DP;
    Arthritis Rheum; 2005 Feb; 52(2):592-600. PubMed ID: 15692967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daily cyclophosphamide for scleroderma: are patients with the most to gain underrepresented in this trial?
    Wells AU; Latsi P; McCune WJ
    Am J Respir Crit Care Med; 2007 Nov; 176(10):952-3. PubMed ID: 17984310
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.
    Tashkin DP; Elashoff R; Clements PJ; Roth MD; Furst DE; Silver RM; Goldin J; Arriola E; Strange C; Bolster MB; Seibold JR; Riley DJ; Hsu VM; Varga J; Schraufnagel D; Theodore A; Simms R; Wise R; Wigley F; White B; Steen V; Read C; Mayes M; Parsley E; Mubarak K; Connolly MK; Golden J; Olman M; Fessler B; Rothfield N; Metersky M; Khanna D; Li N; Li G;
    Am J Respir Crit Care Med; 2007 Nov; 176(10):1026-34. PubMed ID: 17717203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide.
    Akesson A; Scheja A; Lundin A; Wollheim FA
    Arthritis Rheum; 1994 May; 37(5):729-35. PubMed ID: 8185701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre.
    Beretta L; Caronni M; Raimondi M; Ponti A; Viscuso T; Origgi L; Scorza R
    Clin Rheumatol; 2007 Feb; 26(2):168-72. PubMed ID: 16614793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations.
    Kowal-Bielecka O; Kowal K; Rojewska J; Bodzenta-Lukaszyk A; Siergiejko Z; Sierakowska M; Sierakowski S
    Ann Rheum Dis; 2005 Sep; 64(9):1343-6. PubMed ID: 16100339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease.
    Silver RM; Warrick JH; Kinsella MB; Staudt LS; Baumann MH; Strange C
    J Rheumatol; 1993 May; 20(5):838-44. PubMed ID: 8336309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease.
    Várai G; Earle L; Jimenez SA; Steiner RM; Varga J
    J Rheumatol; 1998 Jul; 25(7):1325-9. PubMed ID: 9676764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
    Wanchu A; Suryanaryana BS; Sharma S; Sharma A; Bambery P
    Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma.
    Davas EM; Peppas C; Maragou M; Alvanou E; Hondros D; Dantis PC
    Clin Rheumatol; 1999; 18(6):455-61. PubMed ID: 10638770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis.
    Colaci M; Sebastiani M; Giuggioli D; Manfredi A; Spagnolo P; Luppi F; Richeldi L; Ferri C
    Scand J Rheumatol; 2010 Mar; 39(2):155-9. PubMed ID: 20059446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease.
    Kowal-Bielecka O; Distler O; Kowal K; Siergiejko Z; Chwiećko J; Sulik A; Gay RE; Łukaszyk AB; Gay S; Sierakowski S
    Arthritis Rheum; 2003 Jun; 48(6):1639-46. PubMed ID: 12794832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II.
    Volkmann ER; Tashkin DP; Sim M; Li N; Khanna D; Roth MD; Clements PJ; Hoffmann-Vold AM; Furst DE; Kim G; Goldin J; Elashoff RM
    J Rheumatol; 2019 Oct; 46(10):1316-1325. PubMed ID: 30770517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial changes in scleroderma and idiopathic interstitial lung disease.
    Colp CR; Riker J; Williams MH
    Arch Intern Med; 1973 Oct; 132(4):506-15. PubMed ID: 4742404
    [No Abstract]   [Full Text] [Related]  

  • 18. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis.
    Mittal G; Udwadia Z; Joshi VR
    J Rheumatol; 2003 May; 30(5):1121-2; author reply 1122. PubMed ID: 12734923
    [No Abstract]   [Full Text] [Related]  

  • 19. Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dysfunction (Raynaud's phenomenon) in a case of early systemic sclerosis.
    Casale R; Generini S; Luppi F; Pignone A; Matucci-Cerinic M
    Arthritis Rheum; 2004 Aug; 51(4):665-9. PubMed ID: 15334442
    [No Abstract]   [Full Text] [Related]  

  • 20. Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?
    Bérezné A; Valeyre D; Ranque B; Guillevin L; Mouthon L
    Ann N Y Acad Sci; 2007 Sep; 1110():271-84. PubMed ID: 17911442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.